MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.44
+0.74
+2.33%
After Hours: 32.44 0 0.00% 16:00 05/14 EDT
OPEN
31.64
PREV CLOSE
31.70
HIGH
32.64
LOW
31.32
VOLUME
313.08K
TURNOVER
--
52 WEEK HIGH
71.45
52 WEEK LOW
28.58
MARKET CAP
1.49B
P/E (TTM)
-10.4733
1D
5D
1M
3M
1Y
5Y
UPDATE 1-Biogen's experimental eye treatment fails to meet study goal
reuters.com · 1d ago
uniQure's AAV5 gene therapy shows clinical benefit in hemophilia B patients with pre-existing NAbs
UniQure (QURE) has presented 26-week clinical data from the Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to
Seekingalpha · 2d ago
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~
GlobeNewswire · 3d ago
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 5d ago
uniQure EPS misses by $0.03, misses on revenue
uniQure (QURE): Q1 GAAP EPS of -$0.91 misses by $0.03.Revenue of $0.45M (+350.0% Y/Y) misses by $1.84M.Press Release
Seekingalpha · 5d ago
uniQure Q1 EPS $(0.91) Down From $(0.63) YoY, Sales $454.00K Up From $104.00K YoY
uniQure (NASDAQ:QURE) reported quarterly losses of $(0.91) per share. This is a 44.44 percent decrease over losses of $(0.63) per share from the same period last year. The company reported $454.00 thousand in sales this
Benzinga · 6d ago
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~
GlobeNewswire · 6d ago
uniQure Reports Wider Q1 Net Loss, Higher Revenue
MT Newswires · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QURE. Analyze the recent business situations of Uniqure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QURE stock price target is 68.02 with a high estimate of 100.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 266
Institutional Holdings: 40.49M
% Owned: 88.00%
Shares Outstanding: 46.02M
TypeInstitutionsShares
Increased
46
1.40M
New
13
552.79K
Decreased
25
702.12K
Sold Out
22
1.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Non-Executive Chairman/Independent Director
philip Astley-Sparke
Non-Executive Chairman/Independent Director
Philip Astley-Sparke
President
Ricardo Dolmetsch
Chief Executive Officer/Chief Financial Officer/Executive Director
Matthew Kapusta
Executive Vice President
Alexander Kuta
Executive Director
Robert Gut
Director
Leonard Post
Non-Executive Independent Director
Madhavan Balachandran
Non-Executive Independent Director
Jack Kaye
Non-Executive Independent Director
David Meek
Non-Executive Independent Director
Paula Soteropoulos
Non-Executive Independent Director
Jeremy Springhorn
No Data
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.